ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325 - Quiz - MDSpire

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

Share

Original Source(s)

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

  • June 26, 2026

Related Content

Troponin for surveillance of immune checkpoint inhibitor–associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis

Adrenal tumor microenvironment: hormone–immune crosstalk, molecular heterogeneity, and immunotherapeutic opportunities

Management challenges in metachronous bilateral breast cancer with discordant receptor status: a case report